arrow
G

Gerald S. Falchook

Sarah Cannon Research Institute
H指数:68
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer

AZD2811在复发/难治性小细胞肺癌的I期剂量扩展研究中通过生物标志物分析进行疗效监测

2026-04-030
OAAI
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial

Ifinatamab deruxtecan,一种B7-H3靶向抗体—药物偶联物,在晚期实体瘤患者中的研究(IDeate-PanTumor01):一项1/2期试验的剂量递增结果

2026-03-300
PRE
Phase 1b and Dose-Expansion Study of GSK3326595, a PRMT5 Inhibitor as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cancers

GSK3326595的1b期和剂量扩展研究,PRMT5抑制剂作为单一疗法并与Pembrolizumab联合用于晚期癌症患者

2025-09-090
PREAI
Safety, Tumor Homing And Immune Effects Of Systemically Administered Vocimagene Amiretrorepvec In Patients With Advanced Solid Tumors: A Phase 1B Study

安全性、肿瘤归巢及免疫效应:系统性给予vocimagene amiretrorepvec治疗晚期实体瘤患者的1B期研究

2025-08-210
OAAI
A novel approach for first-in-human dose selection using population dose-response modelling to find a minimum anticipated biological effect level

一种利用群体剂量-反应模型确定最小预期生物效应水平,以进行首次人体试验剂量选择的新方法

2025-04-270
PRE
Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/ metastatic solid tumors: Data from phase I dose escalation

Dazostinag (TAK-676) 单药及联合 pembrolizumab (pembro) 治疗 advanced/metastatic solid tumors 患者(pts)的疗效:来自 phase I dose escalation 研究的数据

2024-09-011
PRE
First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors

首次人体I期试验:评估溶瘤单纯疱疹病毒ONCR-177单药或联合帕博利珠单抗治疗晚期实体瘤的效果

2024-09-010
PRE
NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study

NKT2152,一种新型的口服HIF-2α抑制剂,在既往接受过治疗的晚期透明细胞肾癌(accRCC)患者(pts)中的初步结果:一项I/II期研究

2024-09-012
PRE
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors

尼拉帕尼片在晚期实体瘤患者中的相对生物利用度,生物等效性和食物效应研究

2024-03-010
OAAI
Pharmacokinetics and pharmacodynamics of IGM-8444, a first-in-class engineered pentameric DR5-targeting agonist IgM monoclonal antibody, in patients with R/R and newly diagnosed cancers
2023-12-010
PRE
A randomized Phase 1b study of IGM-8444 in combination with FOLFIRI plus bevacizumab compared to FOLFIRI plus bevacizumab alone in second line metastatic colorectal cancer
2023-12-011
PRE